Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Patients with CA125 response or stabilization

From: A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer

Pt. Age Prior chemo regimens Response latest treatment Interval since latest treatment CA125 at study entry (U/mL) CA125 baseline for response (U/mL) CA125 nadir (U/mL) CA125 response (duration) CT scan response On study
       (study day) (study day)    
Confirmed
202 76 4 PD 28 wks 507 507 379 Stable 23 wks Target lesions stable at 24 weeks but new non-measurable lymphadenopathy 23 wks
(d1) (d91)
208 58 1 PR 56 wks 4939 4939 2326 Minor 10 wks Non-measurable disease only (ascites). New pleural effusion at 28 weeks 34 wks
(d1) (d161) Stable 32 wks
219 48 1 CR 54 wks 214 408 189 Major 10 wks No abnormality on baseline or follow up scans 68 wks
(d55) (d163) Stable 57 wks
228 62 3 plus immuno-therapy PD 16 wks 1455 2215 98 Major 71 wks 32% increase in measurable disease at 12 weeks, reduced to 24% at 28 weeks and 21% at 42 weeks 80 wks
(d33) (d161)
Unconfirmed
220 54 3 PR 20 wks 593 2442 1387 Minor 7 wks At 14 weeks target lesions stable but new ascites 21 wks
       (d55) (d90) Stable 11 wks